Merck Slashes Jobs in $3 Billion Restructuring to Weather Sales Slump

See All Articles

5 Key Take Aways

• Merck will cut jobs as part of a $3 billion annual cost-reduction plan to be achieved by 2027.
• The restructuring will affect administrative, sales, and R&D positions, but the company will continue hiring in strategic growth areas.
• Merck is reducing its global real estate footprint and optimizing its manufacturing network as part of the plan.
• The move comes amid declining sales of its HPV vaccine Gardasil and anticipation of generic competition for its top-selling cancer drug Keytruda.
• Savings from the cuts will be reinvested into developing and launching new medicines to support future growth.

Merck Announces Major Job Cuts as Part of $3 Billion Cost-Saving Plan
Big changes are coming to one of America’s largest pharmaceutical companies. Merck, a well-known name in the world of medicine, has just announced that it will be cutting jobs as part of a massive plan to save $3 billion every year by 2027. Here’s what you need to know about what’s happening and why.
Why is Merck Cutting Jobs?
Merck is facing some tough times. The company’s sales have taken a hit, especially when it comes to its HPV vaccine, Gardasil. In the second quarter of this year, Gardasil sales dropped by a whopping 55% compared to last year. This was mainly because fewer people in China are getting the vaccine, and there’s more competition from cheaper, generic versions in other countries.
At the same time, Merck’s overall revenue for the quarter was $15.8 billion, which is actually a bit lower than last year. Even though this was still better than what experts had predicted, it’s clear that the company needs to tighten its belt.
What’s the Plan?
To deal with these challenges, Merck has approved a new restructuring program. This means they’ll be eliminating some jobs, especially in administrative, sales, and research & development (R&D) departments. The company hasn’t said exactly how many people will be affected, but they did mention that they’ll still be hiring for new roles in areas where the business is growing.
Merck is also planning to reduce its “global real estate footprint”—in other words, they’ll be closing or downsizing some offices and facilities around the world. They’re also looking to make their manufacturing process more efficient.
What Will Merck Do With the Savings?
The $3 billion Merck hopes to save each year isn’t just going into their pockets. The company says it plans to reinvest this money into developing and launching new medicines. This is especially important because their top-selling cancer drug, Keytruda, will soon face competition from generic versions, which could hurt sales.
What Else is Going On?
This announcement comes at a time when the US government is making changes to trade rules, including new tariffs on medicines imported from the European Union. There’s also talk of even higher tariffs in the future, which could impact companies like Merck.
In short, Merck is making some tough decisions now to prepare for a challenging future. While job cuts are never easy, the company hopes these changes will help it stay strong and continue to bring new medicines to market.

Read more